INT23375

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.47
First Reported 1985
Last Reported 2010
Negated 0
Speculated 4
Reported most in Abstract
Documents 17
Total Number 21
Disease Relevance 6.02
Pain Relevance 6.46

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (ENG) cell motility (ENG) cell adhesion (ENG)
nucleolus (ENG) nucleus (ENG) cytoplasm (ENG)
Anatomy Link Frequency
central nervous system 2
arcuate nucleus 1
lateral 1
melanocyte 1
stem cell 1
ENG (Homo sapiens)
Pain Link Frequency Relevance Heat
Opioid 82 100.00 Very High Very High Very High
Enkephalin 17 100.00 Very High Very High Very High
Central nervous system 15 100.00 Very High Very High Very High
Analgesic 11 100.00 Very High Very High Very High
narcan 35 99.66 Very High Very High Very High
substance P 6 99.62 Very High Very High Very High
opioid receptor 7 99.52 Very High Very High Very High
depression 54 99.06 Very High Very High Very High
Neuropeptide 6 98.74 Very High Very High Very High
opiate 10 97.64 Very High Very High Very High
Disease Link Frequency Relevance Heat
Reprotox - General 1 58 100.00 Very High Very High Very High
Pulmonary Disease 327 99.32 Very High Very High Very High
Depression 51 99.06 Very High Very High Very High
Phobia 3 98.72 Very High Very High Very High
Incontinence 2 96.68 Very High Very High Very High
Lung Cancer 21 95.76 Very High Very High Very High
Pain 69 94.64 High High
Dementia 3 94.04 High High
Ulcers 7 92.36 High High
Diabetic Foot Ulcer 2 91.68 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Recombinant IL-1s, however, significantly enhanced specific binding of 125I-beta-endorphin (125I-beta-END) and of D-ala2-(tyrosyl-3,5-3H)enkephalin-(5-D-leucine) (3H-D-ALA), equipotently and in a concentration-dependent manner with maximal activity occurring at a concentration of 10 LAF units/ml.
END Binding (binding) of associated with enkephalin
1) Confidence 0.47 Published 1989 Journal J. Neurosci. Res. Section Abstract Doc Link 2468786 Disease Relevance 0 Pain Relevance 0.56
Dissociated cells from the biopsy specimen were analyzed by flow cytometry after staining with Annexin V and an anti-CD105 antibody.
CD105 Spec (analyzed) Binding (staining) of
2) Confidence 0.36 Published 2007 Journal World J Urol Section Abstract Doc Link 17554544 Disease Relevance 1.09 Pain Relevance 0.55
The increased binding of 125I-beta-END and 3H-D-ALA was blocked steroselectively by (-)-naloxone and by etorphine, suggesting detection of opiate receptors.
END Binding (binding) of associated with narcan, opiate and immobilon
3) Confidence 0.35 Published 1989 Journal J. Neurosci. Res. Section Abstract Doc Link 2468786 Disease Relevance 0 Pain Relevance 0.70
Mononuclear cells were cultured for a minimum of five passages and characterized by cell-surface markers showing CD90+, CD105+, and CD34(-).
CD105 Binding (showing) of in Mononuclear cells
4) Confidence 0.32 Published 2009 Journal Rejuvenation Res Section Abstract Doc Link 19929258 Disease Relevance 1.23 Pain Relevance 0.27
Because beta-END can apparently bind to and activate cellular functions by nonopiate receptors, N-acetyl-beta-END was tested.
beta-END Binding (bind) of
5) Confidence 0.26 Published 1987 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 3039121 Disease Relevance 0 Pain Relevance 0.35
The major etiological theories of depression include brain regions and neural systems that interact with opioid systems and beta-END.
beta-END Binding (interact) of in neural associated with depression and opioid
6) Confidence 0.22 Published 2009 Journal Neuropeptides Section Abstract Doc Link 19647870 Disease Relevance 0.63 Pain Relevance 0.19
It is certainly permissible for persons to treat each other as means so long as they are, simultaneously, treating each other as ends in themselves.a Therefore, I will assume that what Novak means here is that destroying embryos for stem cell research completely dehumanizes them and treats them solely as a means to an end.
an end Binding (means) of in stem cell
7) Confidence 0.19 Published 2008 Journal Philos Ethics Humanit Med Section Body Doc Link PMC2263072 Disease Relevance 0 Pain Relevance 0
Thus, beta-END and IMN bind to common NAL-insensitive binding sites on T lymphocytes and enhance Con A-induced proliferation of these cells.
beta-END Binding (bind) of in T lymphocytes associated with narcan
8) Confidence 0.16 Published 2002 Journal Biochem. Biophys. Res. Commun. Section Abstract Doc Link 11944884 Disease Relevance 0 Pain Relevance 0.46
Endoglin signaling in prostate cancer was shown by our group to be dependent upon the type I TGF-?
Endoglin Binding (group) of associated with reprotox - general 1
9) Confidence 0.14 Published 2010 Journal Cancer Metastasis Rev Section Body Doc Link PMC2933845 Disease Relevance 0.52 Pain Relevance 0
Another significant barrier is that healthcare professionals are reluctant to engage in end of life discussions because of fear of destroying patientsÂ’ hope and also patientsÂ’ trust in them (Selecky et al 2005).
end Binding (engage) of associated with phobia
10) Confidence 0.10 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2528206 Disease Relevance 0.18 Pain Relevance 0
How can good EOL care be provided when it is not clear that the end of life is approaching?
end Spec (clear) Binding (approaching) of
11) Confidence 0.08 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2528206 Disease Relevance 1.13 Pain Relevance 0.05
Barriers to good end of life care in COPD
end Binding (Barriers) of associated with pulmonary disease
12) Confidence 0.08 Published 2008 Journal International Journal of Chronic Obstructive Pulmonary Disease Section Body Doc Link PMC2528206 Disease Relevance 1.11 Pain Relevance 0.09
Beta-endorphin (beta-end) is a potent analgesic peptide which exhibits a variety of pharmacological activities in the central nervous system (CNS) following binding of its N-terminus to specific opioid receptors.
beta-end Binding (binding) of in central nervous system associated with analgesic, opioid receptor and central nervous system
13) Confidence 0.08 Published 1989 Journal Immunopharmacology Section Abstract Doc Link 2540118 Disease Relevance 0 Pain Relevance 0.44
The data suggest that beta-end interacts with a non-opioid receptor which has specificity characteristics strikingly similar to non-opioid receptors characterized in CNS tissue.
beta-end Binding (interacts) of in CNS associated with central nervous system and opioid receptor
14) Confidence 0.07 Published 1989 Journal Immunopharmacology Section Abstract Doc Link 2540118 Disease Relevance 0 Pain Relevance 0.56
The response of TSH and its subunits to NAL and the lack of interaction with beta h-End might be explained by the existence of different types of opiate receptors.
h-End Binding (interaction) of associated with narcan and opiate
15) Confidence 0.02 Published 1985 Journal Acta Endocrinol. Section Abstract Doc Link 2412379 Disease Relevance 0 Pain Relevance 0.61
The morphological support of interactions between enkephalins and three systems--beta-endorphin (beta-END), tyrosine hydroxylase (TH), or neuropeptide Y (NPY)--well represented in the arcuate nucleus, was examined by using an electron microscopic double immunostaining combining two sensitive chromogens, diaminobenzidine (DAB) and tetramethylbenzidine (TMB).
beta-END Binding (interactions) of in arcuate nucleus associated with neuropeptide and enkephalin
16) Confidence 0.02 Published 1994 Journal Peptides Section Abstract Doc Link 7984509 Disease Relevance 0 Pain Relevance 0.15
A time course study demonstrated that pretreatment with beta h-endorphin (beta h-End) (10(-7) M) initiated an inhibitory effect on LH release at 24 h, and was more evident at 48 h.
h-End Spec (evident) Binding (pretreatment) of
17) Confidence 0.01 Published 1986 Journal Life Sci. Section Abstract Doc Link 2935695 Disease Relevance 0 Pain Relevance 0.42
A time course study demonstrated that pretreatment with beta h-endorphin (beta h-End) (10(-7) M) initiated an inhibitory effect on LH release at 24 h, and was more evident at 48 h.
h-End Spec (evident) Binding (pretreatment) of
18) Confidence 0.01 Published 1986 Journal Life Sci. Section Abstract Doc Link 2935695 Disease Relevance 0 Pain Relevance 0.42
This efficient association with the plus-end protein(s) may support an efficient capture of tubulin molecules or enhancing lateral interactions between individual protofilaments.
plus-end Binding (association) of in lateral
19) Confidence 0.01 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2860155 Disease Relevance 0.06 Pain Relevance 0
Potential mechanism of high growth rate of these microtubules can be realized via their selective and more stable binding to the plus-end protein(s).
plus-end Binding (binding) of
20) Confidence 0.01 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2860155 Disease Relevance 0.06 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox